Please login to the form below
Hemlibra
This page shows the latest Hemlibra news and features for those working in and with pharma, biotech and healthcare.
Genentech announces positive phase 3 trial results for haemophilia A
Results from the study showed that Hemlibra demonstrated ‘clinically meaningful’ bleed control in patients with moderate or mild haemophilia A, without factor VIII inhibitors. ... EMA) to update the label for Hemlibra to include non-severe
Latest news
-
Roche to present new data for its drug Polivy at the American Society of Hematology’s annual meeting
Finally, interim data from the phase 3 HAVEN 6 study will be presented at the ASH meeting showing that Hemlibra (emicizumab) had a favourable safety and efficacy profile for people with
-
Roche cites COVID-19 and biosimilars in Q2 decline
Although sales of Roche's newer drugs climbed by 37%, including haemophilia A treatment Hemlibra (emicizumab), multiple sclerosis therapy Ocrevus (ocrelizumab) and PD-1 inhibitor Tecentriq (atezolizumab), this was unable to ... In fact, uptake of both
-
New data reinforces safety profile of Roche’s Hemlibra
New data from a phase 3b study reinforces the safety profile of blockbuster haemophilia A treatment Hemlibra, according to Roche’s Genentech division. ... Further new interim data suggests that people on Hemlibra may also be able to undergo certain
-
Novo Nordisk hits pause on rival to Hemlibra for haemophilia
Concizumab is a potential rival to Roche’s blockbuster Hemlibra (emicizumab), the first non-clotting factor therapy for haemophilia A to reach the market, although it targets a different part of ... Hemlibra meanwhile binds to activated Factor IX and
-
Roche posts minor sales miss in Q4 as biosimilar pressure grows
Schwan highlighted four of these newer Roche medicines as driving the sales growth, namely Perjeta (pertuzumab) for HER2-positive breast cancer, Ocrevus (ocrelizumab) for multiple sclerosis, haemophilia therapy Hemlibra (emicizumab) and
More from news
Approximately 17 fully matching, plus 30 partially matching documents found.
Latest Intelligence
-
Novo Nordisk awakens its ‘Sleeping Beauty’
Competition is real life. Haemophilia is a crowded market and Roche’s success with Hemlibra has squeezed margins across this sector of pharma.
More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.
Subscribe to our email news alerts
-
Senior Medical Writer
- Highly competitive salary
- Associate Director - Global Healthcare Consulting
- Highly competitive salary
-
Pharmacovigilance Project Lead
- Highly competitive salary
- Strategy Director - Healthcare Advertising
- Highly competitive salary
- Early Access Program - Regulatory Affairs (EAP-RA)
- Highly competitive salary
-
Omnichannel Account Director
- £55,000 - £65,000 yearly
-
Pharmacovigilance Manager
- Highly competitive salary
-
Technical Sales Representative
- Highly competitive salary
- MHRA to introduce new UK clinical trials framework
- Roche and Eli Lilly to collaborate on Alzheimer’s disease blood test
- Novo Nordisk suspended from ABPI over ‘serious’ code of practice breaches
- 2023 PM Society Awards – winners announced
- AbbVie’s Parkinson’s disease therapy application rejected by FDA
- Pfizer pays Royalty Pharma $475m following US approval of migraine nasal spray
- Humancomms for humancare?
- AstraZeneca/MSD’s Lynparza combination approved in UK for prostate cancer
- WHO report highlights impact of COVID-19 pandemic on non-communicable diseases
- Critical success factors and the increasing value of rare disease clinical trials
- Quantum Computing, Artificial Intelligence, & Machine Learning for Drug Discovery
- Novo Nordisk and Dewpoint partner on insulin resistance drug candidates
- Team ITG appoints Gerhard Arnhofer as head of customer strategy for life sciences division
- Locus Biosciences announces first patient treated in urinary tract infection trial
- Trust me, I’m from pharma
- DIGITAL EXPERIENCES: LEARNINGS FROM OUTSIDE PHARMA
- Genmab hires first chief operating officer
- A relentless commitment to neuroscience
PMHub
Origins - The Patient Focused Specialists
Origins creates and delivers patient focused strategy, insights, data and solutions, which guides pharma and biotech companies to improve value...
Latest intelligence
- Humancomms for humancare?
- Paul Hutchings, founder of fox&cat, writes on the role of humour in healthcare comms: PharmaComms 2023...
- Rare diseases: not so rare after all
- The brave new world addressing rare diseases – a way ahead to better and more inclusive treatment...
- Webinar: Evolving Patient Journeys - How to generate deeper insights in a changing healthcare landscape
- Register now for part one in a series, Evolving Patient Journeys, in which our experts look at the main ways in which the patient journey has evolved in recent years....
